PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
16.61%
Some net income increase while AGEN is negative at -44.19%. John Neff would see a short-term edge over the struggling competitor.
4.17%
Some D&A expansion while AGEN is negative at -5.93%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
-100.00%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
-2.08%
Negative yoy SBC while AGEN is 45.81%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-115.45%
Both reduce yoy usage, with AGEN at -106.21%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-138.13%
Negative yoy AP while AGEN is 146.71%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-68.80%
Negative yoy usage while AGEN is 59.13%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
119.47%
Well above AGEN's 219.13%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
9.84%
Some CFO growth while AGEN is negative at -20.10%. John Neff would note a short-term liquidity lead over the competitor.
98.37%
CapEx growth well above AGEN's 76.50%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
98.37%
Investing outflow well above AGEN's 76.50%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
64.41%
We repay more while AGEN is negative at -4.70%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
-34.38%
Negative yoy issuance while AGEN is 143.53%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.